Öztürk A A, Çevikelli T, Tilki E K, Güven U M, Kıyan H T
Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Çukurova University, Adana, Türkiye.
Curr Drug Deliv. 2023;20(6):830-840. doi: 10.2174/1567201820666230125144133.
Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug from the heteroaryl acetic acid derivatives family. The most widely used new nanotechnological approaches for topical drug delivery are polymeric nanoparticles (NPs).
Successful results have been obtained with low doses in many treatments, such as cancer, antimicrobial, pain, made with nanoparticle formulations of drug active ingredients.
NPs were prepared using Nano Spray-Dryer. The cytotoxicity of the optimum formulation in BJ (ATCC® CRL-2522™) human fibroblast cells was determined by the WST- 1 method and the gene activity was elucidated by mRNA isolation and real-time polymerase chain reaction (RT-PCR). The in vivo HET- CAM assay was performed for anti-inflammatory activity.
NPs presented PDI values lower than 0.5, and therefore particle size distribution was decided to be monodisperse. Positive zeta potential values of NPs highlighted the presence of the cationic ammonium group of Eudragit® RS 100. The release rates observed from KT-NP coded formulations after 24 hours were 78.4% ± 2.9, demonstrating extended release from all formulations, relative to pure KT. The lowest concentration of KT-NP increased fibroblast cell proliferation higher than the highest concentration of KT. The 5-fold increased effect of KT-NP formulation on collagen gene expression compared to KT is also related to the enhanced anti-inflammatory effect in line with the in vivo HET-CAM assay results.
With the obtained cell viability, gene expression, and HET-CAM results, it has the hope of a successful nano-topical formulation, especially in both wound healing and anti-inflammatory treatment.
酮咯酸氨丁三醇(KT)是一种来自杂芳基乙酸衍生物家族的非甾体抗炎药。用于局部给药的最广泛使用的新型纳米技术方法是聚合物纳米颗粒(NPs)。
在许多治疗中,如癌症、抗菌、疼痛治疗,药物活性成分的纳米颗粒制剂使用低剂量已取得成功结果。
使用纳米喷雾干燥器制备纳米颗粒。通过WST-1法测定最佳制剂在BJ(ATCC® CRL-2522™)人成纤维细胞中的细胞毒性,并通过mRNA分离和实时聚合酶链反应(RT-PCR)阐明基因活性。进行体内鸡胚绒毛尿囊膜(HET-CAM)试验以检测抗炎活性。
纳米颗粒的多分散指数(PDI)值低于0.5,因此粒径分布被确定为单分散。纳米颗粒的正zeta电位值突出了Eudragit® RS 100阳离子铵基团的存在。24小时后从KT-NP编码制剂中观察到的释放率为78.4%±2.9,相对于纯KT,表明所有制剂均具有缓释特性。KT-NP的最低浓度比KT的最高浓度更能促进成纤维细胞增殖。与KT相比,KT-NP制剂对胶原蛋白基因表达的增强作用提高了5倍,这也与体内HET-CAM试验结果一致,表明其抗炎作用增强。
根据获得的细胞活力、基因表达和HET-CAM结果,有望成功制备纳米局部制剂,尤其是在伤口愈合和抗炎治疗方面。